PT  - JOURNAL ARTICLE
AU  - Mi Kyung Kim
AU  - Bo Sung Yoon
AU  - Hyun Park
AU  - Seok Ju Seong
AU  - Hyun Hoon Chung
AU  - Jae Weon Kim
AU  - Soon Beom Kang
TI  - Conservative Treatment With Medroxyprogesterone Acetate Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women: Pilot Study
AID  - 10.1111/IGC.0b013e3181fd9a06
DP  - 2011 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 673--677
VI  - 21
IP  - 4
4099  - http://ijgc.bmj.com/content/21/4/673.short
4100  - http://ijgc.bmj.com/content/21/4/673.full
SO  - Int J Gynecol Cancer2011 Apr 01; 21
AB  - Objective: To assess the feasibility of using medroxyprogesterone acetate (MPA) and levonorgestrel intrauterine system (LNG-IUS) to treat early-stage endometrial cancer in young women who want to preserve their reproductive potential.Methods: Prospective observational study of 5 young patients (mean [SD] age, 38.4 [4.8] years; range, 33-41 years) with a grade 1 endometrial cancer that is presumably confined to the endometrium. The subjects were given a daily oral dose of 500 mg of MPA and LNG-IUS placement. They were followed with dilation and curettage every 3 months.Results: Complete remission was shown in 4 of 5 patients, and one patient showed partial remission. Biopsy results were negative in 2 patients at 3 months, in 1 patient at 6 months, and in 1 patient at 12 months. No treatment-related complications occurred. No recurrence was found during the follow-up period (mean [SD], 10.2 [3.6] months; range, 6-16 months).Conclusions: The concomitant use of MPA with LNG-IUS is feasible for conservative treatment of early-stage endometrial cancer in young women who want to preserve their reproductive potential.